, and Gerolama Condorelli c Purpose of review Contrast-induced acute kidney injury (CI-AKI) is an impairment of renal function following contrast media administration in the absence of an alternative cause. It represents a powerful predictor of poor early and late outcomes. Here, we review the major strategies to prevent CI-AKI.
INTRODUCTION
Iodinated contrast media are usually well tolerated; however, in some patients, they may induce acute kidney injury (AKI). Contrast-induced AKI (CI-AKI) accounts for approximately 10% of all causes of hospital-acquired renal failure, causes a prolonged in-hospital stay and represents a powerful predictor of poor early and late outcome. CI-AKI is defined as an impairment of renal function following contrast media administration in the absence of alternative causes [1] . Moreover, patients developing CI-AKI are at a higher risk of both a further deterioration of kidney function and an unfavourable clinical outcome [2] . On the basis of the possible mechanisms of CI-AKI, different strategies have been proposed to prevent this complication. This review is focused on the therapeutic strategies and the molecular basis to prevent CI-AKI.
MOLECULAR MECHANISMS OF CONTRAST -INDUCED ACUTE KIDNEY INJURY
Hypoxia, vasoconstriction and cytotoxic effects are the main adverse consequences of contrast media administration. However, the molecular mechanisms underlying CI-AKI have not been completely elucidated.
A toxic effect of contrast media on renal tubules has been shown in both clinical trials and animal experiments [3] [4] [5] [6] . We and others provided evidence that contrast media induce renal cell apoptosis [7] [8] [9] [10] in a dose and time-dependent manner [8, 11] . We observed that the cytotoxic effect, although maximum at 3 h, was mostly (%85%) observed within 15 min of incubation. This finding highlights the importance of strategies limiting the exposure of the kidney to the toxins contained in the contrast agent by generating high urine flow in patients.
Studies in humans indicate that reactive oxygen species (ROS) contribute to CI-AKI [10, 12, 13] . ROS activate c-Jun N-terminal kinases (JNK 1/2), and p38MAPK stress kinases, which contribute to the activation of caspase-9 and caspase-3 and thus of the apoptotic process ( Fig. 1) [8, 14, 15] .
CONTRAST-INDUCED ACUTE KIDNEY INJURY DEFINITION
Serum creatinine (sCr) is still considered the major marker of CI-AKI. The sCr typically peaks 2-5 days after contrast media exposure and returns to baseline or near baseline within 1-3 weeks [16, 17] . The current recommendations for the diagnosis of CI-AKI are reported in Table 1 .Therefore, in all patients at risk, a follow-up sCr should be obtained at 48-72 h following contrast media exposure [16] [17] [18] [19] . This implies an intrinsic delay of treatment of patients who will develop CI-AKI, and, conversely, prolonged hospitals stay in patients who will not develop CI-AKI. Moreover, sCr levels often underestimate the kidney damage. In fact, creatinine excreted in the urine is not solely a result of glomerular filtration but also of renal tubular secretion [20] . This means that changes in sCr will underestimate the true fall in glomerular filtration rate (GFR). Therefore, although the injury induced by contrast media impairs the GFR almost immediately, it requires 24-48 h for the fall in GFR to be reflected in an elevated sCr. Due to these limitations, other biomarkers have been considered and others are under investigation. Cystatin C increases earlier (within 24 h) than sCr [21, 22] . The biomarker most investigated in the setting of CI-AKI is neutrophil gelatinase associated lipocalin (NGAL). NGAL, a
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Evaluation of the prophylaxis of CI-AKI. ubiquitous 25-kDa protein (covalently bound to gelatinase from human neutrophils), is a marker of tubular injury [23, 24] . Serum NGAL (sNGAL) and urine NGAL (uNGAL) levels have been shown to predict AKI in different clinical settings [25] [26] [27] [28] , including CI-AKI [29, 30] . We have found that NGAL at 6 h after contrast media exposure is a reliable marker for ruling out CI-AKI and predicts 1-year mayor adverse effects (MAE; i.e. death and dialysis, unpublished data). Therefore, detection of elevated sNGAL might enable more rapid conventional interventions or the introduction of novel therapies to prevent or effectively treat such otherwise undetected AKI (Fig. 2 ) [31] . . Therapeutic approaches to prevent CI-AKI. The approaches currently used to prevent CI-AKI act through different mechanisms. Antioxidant compounds decrease ROS levels, diuretics increase urine production and thus the expulsion of contrast media, and vasodilators and hydration increase blood flow and, thus, urine volume. ROS, reactive oxygen species. 
WHO ARE THE PATIENTS AT RISK?
Many studies indicate that major risk factors for CI-AKI are patients with preexisting chronic kidney disease (CKD), diabetes mellitus, high total dose of contrast media, heart failure or other cause of reduced renal perfusion, age and anaemia [17, 32, 33] . There is a large variability in CI-AKI rate in the literature. This makes it very difficult to estimate the real risk in each single patient and compare different studies or different prophylactic strategies. In general, a clinically relevant renal function deterioration is negligible in patients with normal renal function (even diabetic individuals). Significant AKI is estimated to be 4-11% in patients with mild to moderate renal insufficiency alone (plasma creatinine between 1.5 and 4.0 mg/dl or 132-352 mmol/l) [17, 32] . This risk, however, may be increased to more than 40% by more advanced renal dysfunction, marked volume depletion, severe heart failure or multiple contrast studies within a 72-h period. Risk is estimated to be 9-38% in patients with mild to moderate renal insufficiency and diabetes mellitus [34, 35] . Risk increases to at least 50% if the baseline plasma creatinine is more than 4 mg/dl (>352 mmol/l), particularly in patients with diabetic nephropathy [32] . In order to help clinicians, some risk scores have been proposed (Table 2 ) [32,36 & ]. The risk score proposed by Mehran et al. [32] is calculated according to the following algorithm: hypotension (integer score 5), intra-aortic balloon pump support (integer score 5), congestive heart failure (integer score 4), age more than 75 years (integer score 4), diabetes mellitus (integer score 3), estimated GFR (eGFR) less than 60 (integer score 2-6), preexisting anaemia (integer score 3) and contrast media volume (integer score 1 for each 100 ml). The global scores of 5 or less, 6-10, 11-16 and at least 16 predict a CI-AKI risk of 7.5, 14, 26.1 and 57.3%, respectively. The risk score proposed by Gurm et al. [36 & ] can be reliably calculated using a novel easy-to-use computational tool (https://bmc2.org/calculators/cin) and differentiate three groups of patients: low risk (<1%), intermediate risk (1-7%) and high risk (>7%). These are very useful in clinical practice for two reasons: first, because they allow a better definition of the risk in each single patient before contrast exposure, and, consequently, they help the clinicians to target the most appropriate prophylactic strategy in each single patient.
STRATEGIES FOR CONTRAST-INDUCED ACUTE KIDNEY INJURY PREVENTION
Multiple lines of evidence suggest that a single intervention strategy may not be successful for CI-AKI prevention. Here, we describe the major strategies developed to prevent CI-AKI.
HYDRATION
Hydration is considered one of the major beneficial measures for CI-AKI prevention [37] . Thus, adequate hydration should be performed before contrast media exposure. Hydration, by inducing an increase of urine flow rates, reduces the concentration of contrast media in the tubule and expedites contrast media excretion. This implies a reduction of the exposure time of tubular cells to the toxic effects of contrast media [38] . A major benefit of hydration is achieved when it is administered intravenously rather than orally [39] and when received for 12 h before and after cardiac catheterization instead of immediately before or during the procedure [40, 41] . Limitations of this hydration regimen include preclusion in urgent/emergent settings and suboptimal efficacy in high and very high risk patients. Optimal hydration regimen should be defined according to a predefined clinical marker. Two markers have been identified: urine flow rate [42] and left ventricular end-diastolic pressure (LVEDP) [43 & ]. CI-AKI, contrast-induced acute kidney injury.
Urine flow rate
High urine flow rate may reduce the incidence of CI-AKI by several effects. It is important to consider that a high urine flow rate should be reached by maintaining a constant intravascular volume to prevent hypovolemia [42] . Data from the PRINCE study indicate that the increase of the urine flow rate (!150 ml/h) reduces the toxic effect of contrast media [42] . 
Left ventricular end-diastolic pressure
The POSEIDON trial [43 & ] sought to determine the efficacy of a novel fluid protocol based upon the LVEDP. Patients undergoing cardiac catheterization with an estimated GFR of 60 ml/min/1.73 m 2 or less and one or more of diabetes mellitus, history of congestive heart failure, hypertension or age more than 75 years were randomly allocated to LVEDPguided volume expansion or control group. Both groups received intravenous 0.9% sodium chloride at 3 ml/kg for 1 h prior to cardiac catheterization. In the LVEDP group, the fluid rate was adjusted according to the LVEDP as follows: 5 ml/kg/h for LVEDP less than 13 mmHg; 3 ml/kg/h for 13-18 mmHg; and 1.5 ml/kg/h for more than 18 mmHg. The control group rate was 1.5 ml/kg/h. For both groups, the fluid rate was set at the start of the procedure, continued during the procedure and for 4 h postprocedure. CI-AKI occurred less frequently among patients randomized to the LVEDP-guided group than the control group (6.7 vs. 16.3%, P ¼ 0.005).
WHICH INTRAVENOUS FLUID?
It is still controversial whether some fluids are superior to others (namely, sodium bicarbonate vs. sodium chloride). Sodium bicarbonate improves urine alkalization and probably decreases the concentration of contrast media in the renal tubules [47] . Two meta-analyses did not identify a benefit of sodium bicarbonate vs. sodium chloride in preventing CI-AKI [48] . In addition, the recent Bicarbonate or Saline Study (BOSS) also failed to demonstrate a benefit of sodium bicarbonate over sodium chloride solution in preventing CI-AKI, although the death rate was lower in the group that received sodium bicarbonate [49] .
ANTIOXIDANT COMPOUNDS
As contrast media exposure of vasa recta and tubule cells cause an increase of ROS production and, consequently, apoptosis activation, compounds with antioxidant proprieties acting as scavenger molecules for ROS [such as N-acetyl cysteine (NAC) and statins] have been investigated.
N-ACETYLCYSTEINE
NAC is a thiol compound classically known as a mucolytic agent, which is used to thin mucus in patients with respiratory disorders. NAC is a potent antioxidant that scavenges a wide variety of oxygenderived free radicals and may be capable of preventing AKI [50] [51] [52] . The results on the use of NAC are conflicting. Initial studies by Tepel et al. [53] showed that NAC (600 mg orally twice daily) and hydration (with normal saline) before and after administration of contrast media was more effective than hydration alone in preventing CI-AKI in patients with CKD undergoing computed tomography. However, a recent large randomized trial [54] failed to demonstrate the superiority of NAC vs. placebo in reducing the incidence of CI-AKI in patients undergoing coronary angiography study. A recent meta-analysis of 30 trials did demonstrate a renoprotective benefit of NAC [55] . Even if the clinical data are controversial, the molecular mechanisms of NAC on CI-AKI prevention have been clearly elucidated in in-vitro experiments. Our studies demonstrate that NAC exerts its antioxidant properties preventing kidney cell death by inhibiting oxygen free radical production and thus stress kinases and apoptosis activation upon contrast media exposure [2, 8, 15, 56, 57] . The protective role of NAC on kidney cells has also been reported in noncontrast media agent induced kidney injury. Thus, larger clinical studies and trials are required to elucidate their potential effect on CI-AKI prevention.
STATINS
Apart from the main use of the 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase inhibitors (statins) to control cholesterol levels, they have several 'pleiotropic' effects through their nonlipidrelated mechanisms. They modulate inflammatory responses, endothelial function, plaque stability, thrombus formation and apoptosis [58] . Several studies have investigated the effectiveness of statins pretreatment in reducing the incidence of CI-AKI [59] [60] [61] [62] [63] . Our study demonstrated that a single high (80 mg) loading dose of atorvastatin administered within 24 h of contrast media exposure is effective in reducing the rate of CI-AKI in patients with CKD [15] . Furthermore, our in-vitro model indicates that the pretreatment with atorvastatin prevents contrast media induced renal cell apoptosis by reducing stress kinases activation and restored the survival signals mediated by Akt and Erks signal transduction pathways [15] . Moreover, recent investigations also confirmed that rosuvastatin in statin-naive patients with both stable and acute coronary syndrome scheduled for early invasive procedure can prevent CI-AKI [63] .
VASODILATOR COMPOUNDS
Several vasodilator drugs have been tested for prevention of CI-AKI, but have not shown any benefit (theophylline [64] , nifedipine [65] , adenosine [66] , endothelin receptor antagonists [67] , atrial natriuretic peptide [68] , dopamine [69] [70] [71] ). A randomized, double-blind, placebo-controlled trial showed that prophylactic administration of iloprost (inhaled prostaglandin I2 analogue approved for the treatment of pulmonary hypertension) in patients with CKD, undergoing coronary angiography and/or intervention, may protect against CI-AKI [72] .
DIURETICS
Compelling data support that neither mannitol nor furosemide offers additional protection against CI-AKI as compared with saline hydration alone in either diabetic or nondiabetic patients. In the study by Solomon and Deray [16] , there were no beneficial effects of the osmotic diuretic mannitol when added to saline hydration in either diabetic or nondiabetic patients, and there was an actual exacerbation of CI-AKI with the use of the loop diuretic furosemide with saline hydration. In a small study of 18 patients, furosemide pretreatment (1.5 mg/kg) added to an intravenous fluid protocol was associated with significantly worse renal function than intravenous fluid alone [73] . Significant weight loss was observed in the patients treated with furosemide, suggesting that the potentially deleterious effect of furosemide was the result of a negative fluid balance. Theoretically, furosemide should protect the kidney by reducing the outer medullary hypoxia caused by contrast media by blocking the Na-K-2Cl transporter in the medullary thick ascending limb [74] . This approach, however, has actually been shown to be deleterious and to increase the rates of CI-AKI [75] . It has been suggested that the deleterious effect observed is a result of a negative fluid balance [73, 75] .
RENAL REPLACEMENT THERAPY
Some data suggest the potential role of hemofiltration for the prevention of CI-AKI in high-risk patients [76] . Concerns, however, have been raised following this study, including that the creatinine removal by the hemofiltration procedure may explain the decreased frequency of elevation in the serum creatinine, their greater intensity of care relative to the control group may explain why hemofiltration was associated with improved short and long-term survival, and that hemofiltration is expensive, logistically cumbersome and associated with significant risks.
REMOTE ISCHEMIC PRECONDITIONING
In addition to the effects of local ischemia, remote ischemia can protect distant organs or tissue during subsequent ischemia [77] . This has been termed remote ischemic preconditioning (RIPC) [78] . RIPC is a method by which the deliberate induction of transient nonlethal ischemia of an organ protects against subsequent ischemic injury of another organ. The potential use of RIPC has been mostly evaluated in the setting of myocardial protection. There are, also, preliminary data suggesting that RIPC prior to both cardiac surgery and contrast media administration protects against AKI [79] . In one randomized, double-blind trial, 100 patients with CKD were subjected to RIPC or to a sham procedure prior to elective coronary angiography [80] . RIPC was induced by intermittent arm ischemia generated by four cycles of 5-min inflation of a blood pressure (BP) cuff to 50 mmHg above individual systolic pressure within 45 min before angiography. The sham procedure consisted of inflation of a BP cuff to individual diastolic pressure, followed by deflation to 10 mmHg. All patients also received acetylcysteine and a continuous physiological saline infusion. The incidence of CI-AKI was 6% in the RIPC group vs. 20% in the sham group [odds ratio (OR) 0.21, 95% confidence interval (95% CI) 0.07-0.57]. In a second trial, 225 patients with a non-ST segment elevation myocardial infarction were randomly assigned to receive RIPC or a sham procedure prior to the coronary intervention [81] . RIPC consisted of four cycles of 30-s inflation, followed by 30 s deflation of the stent balloon during the PCI procedure; the sham procedure consisted of four cycles of 30-s inflation to only 3 atm pressure, followed by deflation. Even in this study, CI-AKI occurred less frequently in the RIPC group than in the sham group (12.4 vs. 29.5%, respectively, OR 0.34, 95% CI 0.16-0.71). These results, although compelling (particularly because RIPC is conferred using different modalities and at different time points prior to contrast exposure), require confirmation in larger randomized trials and before RIPC can be recommended as a preventive measure for CONCLUSION AKI may occur following contrast media exposure, especially in patients with risk factors, including older age, CKD, congestive heart failure and diabetes mellitus. The administration of a limited volume of contrast media and adequate hydration (either by saline or sodium bicarbonate infusion) may prevent CI-AKI. Adequate hydration should be guided according to the urine flow rate and in those patients undergoing coronary angiography perhaps by LVEDPguided fluid replacement. A high dose of statins (atorvastatin or rosuvastatin, or both) may be effective, probably by reducing oxidative stress and therefore preventing renal cell apoptosis. Although the effectiveness of NAC in preventing CI-AKI is still controversial, its antioxidant and antiapoptotic properties may have a clinically appreciable effect in high-risk patients. Despite these strategies, however, CI-AKI may still occur in patients at a high risk. The preliminary and promising results of RIPC require confirmation in larger randomized trials before this strategy can be recommended for CI-AKI prevention. The discovery of novel and reliable markers of CI-AKI may allow early therapeutic interventions and, potentially, a more favourable outcome. In Table 3 , we summarize our approach to prevent CI-AKI.
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